DT2219ARL

BIOLOGICAL2 trials

Sponsors

Masonic Cancer Center, University of Minnesota

Conditions

LeukemiaLymphomaRefractory B-Lineage LeukemiaRefractory B-Lineage LymphomaRelapsed B-Lineage LeukemiaRelapsed B-Lineage Lymphoma

Phase 1

DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma

CompletedNCT00889408

Masonic Cancer Center, University of MinnesotaLeukemia, Lymphoma

Start: 2013-12-02End: 2014-07-21Updated: 2017-12-02

HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma

CompletedNCT02370160

Masonic Cancer Center, University of MinnesotaRefractory B-Lineage Leukemia, Refractory B-Lineage Lymphoma, Relapsed B-Lineage Leukemia +1

Start: 2015-12-21End: 2018-04-08Updated: 2020-01-13

Related Papers

Bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies: Results of phase I-II trial.

Journal of Clinical Oncology2019-05-209 citations